VANCOUVER- Frederick Williams witnessed the worst of the AIDS crisis. Diagnosed with HIV 33 years ago, Williams survived and went on to become a chef and then a harm-reduction workshop leader. But most of his friends weren’t so lucky, and they died from AIDS-related illnesses. “I’ve gone through waves of friends,” the 55-year-old said. “In […]
Scientists tested a costly approach to curbing the AIDS epidemic: Test everyone in the community, and treat anyone who is infected. Imagine that 90 percent of all people living with H.I.V. were diagnosed and treated with drugs. Would that be sufficient to end the AIDS epidemic? Scientists tried to answer the question in three enormous
Intensive Anti-H.I.V. Efforts Meet With Mixed Success in Africa Read More »
A potential vaccine is being welcomed by HIV prevention advocates with ‘cautious optimism’ A vaccine targeting multiple strains of HIV is going into late-stage testing in the US and Europe later this year, but HIV experts have expressed ‘optimistic caution.’ Pharmaceutical giant Johnson & Johnson (J&J) is gearing up to test a new type of
Groundbreaking HIV vaccine enters late-stage testing in US and Europe Read More »
International concern is growing in medical and development circles that the Trudeau government is about to step back from its much-publicized global leadership on eradicating AIDS, tuberculosis and malaria. In 2016, Trudeau announced with fanfare that Canada was contributing $804-million to the Global Fund, a 24-per-cent increase to the international organization that aims to curb
International concern is growing in medical and development circles that the Trudeau government is about to step back from its much-publicized global leadership on eradicating AIDS, tuberculosis and malaria. In 2016, Trudeau announced with fanfare that Canada was contributing $804 million to the Global Fund, a 24-per-cent increase to the international organization that aims to
Global concerns rise over possibility Canada backs out of AIDS fight funding Read More »
The Centers for Disease Control and Prevention announced that PrEP among at-risk men increased 500 percent between 2014 to 2017. And those numbers are expected to rise following Gilead Sciences’ new commitment to donate up to 2.4 million bottles of Truvada to the CDC by 2030 (which amounts to 200,000 per year). The study is
PrEP Use Up 500 Percent In Just Three Years Read More »
The teams participating in the BC-CfE’s Provincial BOOST Collaborative met in June for its third learning session, and is now approaching the halfway point for the quality improvement project aiming to improve engagement in treatment for opioid use disorder.
Since December 2018, when people come in to Interior Health emergency departments and require diagnostic blood work, an HIV test may be included. Provincial testing guidelines encourage primary care providers to know the HIV status of all patients, not only those deemed at risk. The guidelines also advise that when people are sick, an HIV
HIV tests now part of most ED blood work Read More »
The Comparative Outcomes And Service Utilization Trends (COAST) study is a population-based cohort study that aims to examine the health outcomes and health service use of people living with HIV (PLHIV), including both those who are accessing and not accessing antiretroviral therapy, as compared to the general population of British Columbia. The study comprises two
Comparative Outcomes And Service Utilization Trends (COAST) Fact Sheet Read More »
Gay Men of African Descent on hiatus as its aims to shift funding model A Brooklyn organization that focuses on HIV prevention and sexual health among African-American gay and bisexual men will go on hiatus for the summer while it reorganizes from its current grant-based funding scheme to a fee-for-service provider model under which it
Financial Woes Face Black HIV Group Read More »
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
